Martin Fleisher

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

Howard I. Scher, Tomasz M. Beer, Celestia S. Higano et al. · The Lancet · 2010 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +13

Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer

Daniel C. Danila, Glenn Heller, Gretchen A. Gignac et al. · Clinical Cancer Research · 2007 · 673 citations

Medicine, Cancer Biology, Oncology +14

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer

Howard I. Scher, David Lu, Nicole A. Schreiber et al. · JAMA Oncology · 2016 · 637 citations · Full text

Medicine, Oncology, Pharmacology +17

Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits

Katharina Brandl, George Plitas, Coralia N. Mihu et al. · Nature · 2008 · 621 citations · Full text

Life Sciences, Immunology, Microbiology +10

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data

Howard I. Scher, Xiaoyu Jia, Johann S. de Bono et al. · The Lancet Oncology · 2009 · 615 citations · Full text

Medicine, Cancer Biology, Oncology +17